Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EIF4E | P06730 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200227 | 0.87 | AR (0.52) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL8799909 | 0.81 | CYP19A1 (0.57) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL11689636 | 0.77 | ALDH1A1 (0.47) | KDM4EMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL6242058 | 0.76 | CDK5 (0.57) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL11466217 | 0.75 | KDM4E (0.86) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL11466274 | 0.74 | CYP19A1 (0.59) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL4281217 | 0.72 | RAB9A (0.75) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL11455457 | 0.72 | RAB9A (0.75) | ARCYP19A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL6249095 | 0.71 | RAB9A (0.50) | CYP19A1KDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3435594 | 0.70 | ACHE (0.54) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-107428690-B | Mutant IDH1 inhibitors useful for the treatment of cancer | 美国政府健康及人类服务部 | 2021-04-13 | — | — | CN | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3237385-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | IDH1, IDH3B, IDH3A | AR 2222/4885CYP19A1 266/4885KDM4E 245/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | AR 2222/4885CYP19A1 266/4885KDM4E 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.